Form 4: Edwards Lifesciences CFO Scott Ullem Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Scott Ullem, CFO of Edwards Lifesciences, exercised stock options and sold shares on March 26, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 26, 2025, Scott B. Ullem, the Chief Financial Officer of Edwards Lifesciences Corp, executed employee stock options to acquire 11,250 shares of common stock at a price of $45.2767 per share.
- Simultaneously, Ullem sold 11,250 shares of common stock at a weighted average price of $70.8682 per share, with individual trades ranging from $70.525 to $71.320.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 19, 2024.
- Following these transactions, Ullem directly owns 30,387 shares and indirectly owns 266,318 shares through a trust.
Sentiment
Score: 5
Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, indicating a neutral sentiment.
Industry Context
Executive stock transactions are common and often pre-planned to comply with insider trading regulations. The use of a 10b5-1 plan allows insiders to sell shares without being accused of acting on non-public information.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- Rule 10b5-1 trading plans are a standard practice among corporate executives to manage their stock sales in a transparent and compliant manner.
- Comparing Ullem's transactions to those of other CFOs in the medical device industry would require analyzing similar Form 4 filings for companies like Medtronic, Abbott, or Stryker.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, as they involve the sale of shares by a key executive.
- The use of a 10b5-1 plan ensures transparency and compliance, which is generally viewed positively by stakeholders.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 03/26/2025 | Date of the stock option exercise and share sale |
| 05/17/2019 | Date the Employee Stock Option was exercisable |
| 05/16/2025 | Date the Employee Stock Option expires |
Keywords
Edwards Lifesciences, Scott Ullem, CFO, stock options, Rule 10b5-1, trading plan, share sale, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.